Novel therapeutic approaches in the treatment of children with hepatoblastoma

Howard M. Katzenstein, Cynthia Rigsby, Peter H. Shaw, Torrey L. Mitchell, Paul Haut, Morris Kletzel

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Hepatoblastoma is the most common liver tumor diagnosed in children. Children with persistently unresectable disease, metastatic disease at presentation, recurrent disease, or slowly declining alpha-fetoprotein levels are at high risk for recurrence, exhibit an extremely poor prognosis, and are in desperate need of novel therapeutic agents and strategies. Four high-risk patients were treated. One patient with a local recurrence was treated with irinotecan followed by orthotopic liver transplant. Three patients were treated with tandem high-dose chemotherapy (HDT) with autologous stem cell rescue (two with primary metastatic disease and one with recurrent disease). All three of the patients treated with HDT had relapse (two of them subsequently received irinotecan); the remaining patient underwent surgical resection of a solitary recurrent pulmonary metastasis. Irinotecan demonstrated significant antitumor effects in all three treated patients and was well tolerated. None of the three patients treated with HDT remained disease-free, although the patient who underwent surgical resection of a solitary recurrent pulmonary metastasis remains disease-free 6 years from diagnosis. Further exploration of the use of irinotecan is warranted in high-risk patients with hepatoblastoma.

Original languageEnglish (US)
Pages (from-to)751-755
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume24
Issue number9
DOIs
StatePublished - Dec 2002
Externally publishedYes

Fingerprint

Hepatoblastoma
irinotecan
Therapeutics
Recurrence
Drug Therapy
Neoplasm Metastasis
Lung
Liver
alpha-Fetoproteins
Stem Cells
Transplants

Keywords

  • Hepatoblastoma
  • High-dose therapy
  • Irinotecan
  • Peripheral blood stem cells
  • Transplant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Novel therapeutic approaches in the treatment of children with hepatoblastoma. / Katzenstein, Howard M.; Rigsby, Cynthia; Shaw, Peter H.; Mitchell, Torrey L.; Haut, Paul; Kletzel, Morris.

In: Journal of Pediatric Hematology/Oncology, Vol. 24, No. 9, 12.2002, p. 751-755.

Research output: Contribution to journalArticle

Katzenstein, Howard M. ; Rigsby, Cynthia ; Shaw, Peter H. ; Mitchell, Torrey L. ; Haut, Paul ; Kletzel, Morris. / Novel therapeutic approaches in the treatment of children with hepatoblastoma. In: Journal of Pediatric Hematology/Oncology. 2002 ; Vol. 24, No. 9. pp. 751-755.
@article{db6e86abc14849899470fe7cd341d1ab,
title = "Novel therapeutic approaches in the treatment of children with hepatoblastoma",
abstract = "Hepatoblastoma is the most common liver tumor diagnosed in children. Children with persistently unresectable disease, metastatic disease at presentation, recurrent disease, or slowly declining alpha-fetoprotein levels are at high risk for recurrence, exhibit an extremely poor prognosis, and are in desperate need of novel therapeutic agents and strategies. Four high-risk patients were treated. One patient with a local recurrence was treated with irinotecan followed by orthotopic liver transplant. Three patients were treated with tandem high-dose chemotherapy (HDT) with autologous stem cell rescue (two with primary metastatic disease and one with recurrent disease). All three of the patients treated with HDT had relapse (two of them subsequently received irinotecan); the remaining patient underwent surgical resection of a solitary recurrent pulmonary metastasis. Irinotecan demonstrated significant antitumor effects in all three treated patients and was well tolerated. None of the three patients treated with HDT remained disease-free, although the patient who underwent surgical resection of a solitary recurrent pulmonary metastasis remains disease-free 6 years from diagnosis. Further exploration of the use of irinotecan is warranted in high-risk patients with hepatoblastoma.",
keywords = "Hepatoblastoma, High-dose therapy, Irinotecan, Peripheral blood stem cells, Transplant",
author = "Katzenstein, {Howard M.} and Cynthia Rigsby and Shaw, {Peter H.} and Mitchell, {Torrey L.} and Paul Haut and Morris Kletzel",
year = "2002",
month = "12",
doi = "10.1097/00043426-200212000-00014",
language = "English (US)",
volume = "24",
pages = "751--755",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Novel therapeutic approaches in the treatment of children with hepatoblastoma

AU - Katzenstein, Howard M.

AU - Rigsby, Cynthia

AU - Shaw, Peter H.

AU - Mitchell, Torrey L.

AU - Haut, Paul

AU - Kletzel, Morris

PY - 2002/12

Y1 - 2002/12

N2 - Hepatoblastoma is the most common liver tumor diagnosed in children. Children with persistently unresectable disease, metastatic disease at presentation, recurrent disease, or slowly declining alpha-fetoprotein levels are at high risk for recurrence, exhibit an extremely poor prognosis, and are in desperate need of novel therapeutic agents and strategies. Four high-risk patients were treated. One patient with a local recurrence was treated with irinotecan followed by orthotopic liver transplant. Three patients were treated with tandem high-dose chemotherapy (HDT) with autologous stem cell rescue (two with primary metastatic disease and one with recurrent disease). All three of the patients treated with HDT had relapse (two of them subsequently received irinotecan); the remaining patient underwent surgical resection of a solitary recurrent pulmonary metastasis. Irinotecan demonstrated significant antitumor effects in all three treated patients and was well tolerated. None of the three patients treated with HDT remained disease-free, although the patient who underwent surgical resection of a solitary recurrent pulmonary metastasis remains disease-free 6 years from diagnosis. Further exploration of the use of irinotecan is warranted in high-risk patients with hepatoblastoma.

AB - Hepatoblastoma is the most common liver tumor diagnosed in children. Children with persistently unresectable disease, metastatic disease at presentation, recurrent disease, or slowly declining alpha-fetoprotein levels are at high risk for recurrence, exhibit an extremely poor prognosis, and are in desperate need of novel therapeutic agents and strategies. Four high-risk patients were treated. One patient with a local recurrence was treated with irinotecan followed by orthotopic liver transplant. Three patients were treated with tandem high-dose chemotherapy (HDT) with autologous stem cell rescue (two with primary metastatic disease and one with recurrent disease). All three of the patients treated with HDT had relapse (two of them subsequently received irinotecan); the remaining patient underwent surgical resection of a solitary recurrent pulmonary metastasis. Irinotecan demonstrated significant antitumor effects in all three treated patients and was well tolerated. None of the three patients treated with HDT remained disease-free, although the patient who underwent surgical resection of a solitary recurrent pulmonary metastasis remains disease-free 6 years from diagnosis. Further exploration of the use of irinotecan is warranted in high-risk patients with hepatoblastoma.

KW - Hepatoblastoma

KW - High-dose therapy

KW - Irinotecan

KW - Peripheral blood stem cells

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=0036899624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036899624&partnerID=8YFLogxK

U2 - 10.1097/00043426-200212000-00014

DO - 10.1097/00043426-200212000-00014

M3 - Article

C2 - 12468918

AN - SCOPUS:0036899624

VL - 24

SP - 751

EP - 755

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 9

ER -